![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Real-World Data on the Use of Ribavirin With Ombitasvir/Paritaprevir/r With or Without Dasabuvir in HCV Genotype 1- or 4-Infected Pati ents From the German Hepatitis C Registry
|
|
|
Reported by jules Levin
EASL 2016 April 14-17 Barcelona
Tania M Welzel1, Peter Buggisch2, Thomas Berg3, Kersti n Stein4, Jan Hetti nger5, Henning Kleine5
1JW Goethe University, Frankfurt, Germany; 2IFI Hamburg, Hamburg, Germany; 3Clinic of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany; 4Ott o-von-Guericke-University Magdeburg, Magdeburg, Germany; 5AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany
![EASL1](../images/042116/042116-6/EASL1.gif)
![EASL2](../images/042116/042116-6/EASL2.gif)
![EASL3](../images/042116/042116-6/EASL3.gif)
![EASL4](../images/042116/042116-6/EASL4.gif)
![EASL5](../images/042116/042116-6/EASL5.gif)
![EASL6](../images/042116/042116-6/EASL6.gif)
![EASL7](../images/042116/042116-6/EASL7.gif)
![EASL8](../images/042116/042116-6/EASL8.gif)
![EASL9](../images/042116/042116-6/EASL9.gif)
![EASL10](../images/042116/042116-6/EASL10.gif)
![EASL11](../images/042116/042116-6/EASL11.gif)
![EASL12](../images/042116/042116-6/EASL12.gif)
![EASL13](../images/042116/042116-6/EASL13.gif)
AE, adverse event; ULN, upper limit of normal. Grading according to CTCAE v4.03. Stated deviati ons in n-values for baseline characteristi cs are
due to missing documentati on in the registry at the ti me of analysis. *Only pneumonia, dyspnoea, and anaemia occurred in more than 1 pati ent
(n = 2 for each). One pati ent was hospitalised following a stroke and died on post-treatment Day 7; a second pati ent died of a myocardial
infarcti on. Neither death was assessed as being related to study drugs. Laboratory testi ng was performed at investi gator's discreti on.
![EASL14](../images/042116/042116-6/EASL14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|